company background image
HAE logo

Haemonetics NYSE:HAE Stock Report

Last Price

US$71.43

Market Cap

US$3.6b

7D

0.3%

1Y

-11.1%

Updated

21 Feb, 2024

Data

Company Financials +

HAE Stock Overview

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally.

HAE fundamental analysis
Snowflake Score
Valuation6/6
Future Growth3/6
Past Performance5/6
Financial Health3/6
Dividends0/6

Haemonetics Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Haemonetics
Historical stock prices
Current Share PriceUS$71.43
52 Week HighUS$95.26
52 Week LowUS$70.74
Beta0.34
1 Month Change-15.72%
3 Month Change-12.87%
1 Year Change-11.06%
3 Year Change-45.31%
5 Year Change-18.02%
Change since IPO1,103.03%

Recent News & Updates

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Recent updates

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09
Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Haemonetics: Upside Case Hinges On Blood Plasma Collection Market

Jun 11

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

May 11
Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Apr 01
Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Jan 28
Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Dec 20
Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Oct 28
Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

Oct 09
Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

We Think Haemonetics (NYSE:HAE) Is Taking Some Risk With Its Debt

Sep 07
We Think Haemonetics (NYSE:HAE) Is Taking Some Risk With Its Debt

Here's Why Shareholders May Want To Be Cautious With Increasing Haemonetics Corporation's (NYSE:HAE) CEO Pay Packet

Jul 31
Here's Why Shareholders May Want To Be Cautious With Increasing Haemonetics Corporation's (NYSE:HAE) CEO Pay Packet

Are Haemonetics Corporation (NYSE:HAE) Investors Paying Above The Intrinsic Value?

Jul 15
Are Haemonetics Corporation (NYSE:HAE) Investors Paying Above The Intrinsic Value?

Haemonetics (NYSE:HAE) Is Experiencing Growth In Returns On Capital

Jun 30
Haemonetics (NYSE:HAE) Is Experiencing Growth In Returns On Capital

Shareholder Returns

HAEUS Medical EquipmentUS Market
7D0.3%1.4%-0.5%
1Y-11.1%11.3%22.3%

Return vs Industry: HAE underperformed the US Medical Equipment industry which returned 8.3% over the past year.

Return vs Market: HAE underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is HAE's price volatile compared to industry and market?
HAE volatility
HAE Average Weekly Movement4.0%
Medical Equipment Industry Average Movement8.1%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: HAE's share price has been volatile over the past 3 months.

Volatility Over Time: HAE's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19713,034Chris Simonhttps://www.haemonetics.com

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system.

Haemonetics Corporation Fundamentals Summary

How do Haemonetics's earnings and revenue compare to its market cap?
HAE fundamental statistics
Market capUS$3.63b
Earnings (TTM)US$126.57m
Revenue (TTM)US$1.27b

28.7x

P/E Ratio

2.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HAE income statement (TTM)
RevenueUS$1.27b
Cost of RevenueUS$582.96m
Gross ProfitUS$687.22m
Other ExpensesUS$560.65m
EarningsUS$126.57m

Last Reported Earnings

Dec 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)2.49
Gross Margin54.10%
Net Profit Margin9.97%
Debt/Equity Ratio92.3%

How did HAE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.